A research team from Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong (HKUMed), has developed a photo-responsive nanomedicine for light-controlled colorectal cancer therapy. The nanoparticles are simply made by self-assembly of a near-infrared dye and a prodrug. After intravenous injection, the nanoparticles can target colon tumours and release drugs to kill cancer cells upon light irradiation. This process can be in-situ monitored by in vivo imaging. The research has been published in Bioengineering & Translational Medicine (link to the publication), and a patent application has been filed based on this work.
According to the statistics from Hong Kong Cancer Registry, colorectal cancer (colon cancer) is the second most common cancer in Hong Kong, accounting for 15.8% of all cancer cases, and there is an upward trend in recent years. Conventional chemotherapy has side effects, including diarrhoea, vomiting, hair loss, anaemia and so on, as anti-cancer drugs are toxic to normal cells and are usually distributed throughout the body after systemic administration. Therefore, it is necessary to develop a precisely controllable drug delivery technology.
Research methods and findings
Light can activate photo-responsive prodrugs specifically at tumour sites, thus reducing side effects in other tissues. In this study, photo-responsive nanoparticles can be prepared by simply mixing the near-infrared cyanine dye IR783 and the photocleavable chlorambucil prodrug BODIPY-Cb. The nanoparticles have high affinity to caveolin (CAV-1), thus can be efficiently taken up by colorectal cancer cells with high CAV-1 expression. Upon green light irradiation, the prodrug is cleaved, and the nanoparticles dissociate, releasing free chlorambucil. This process can be monitored through fluorescence imaging. In colon cancer-bearing mice, tumour growth was significantly inhibited after administration of the nanoparticles and light treatment, and no obvious side effects were observed.
Significance of the study
This study presents a simple yet effective light-triggerable nanomedicine platform for colorectal cancer treatment, of which the nanomedicine can achieve precise delivery of anti-cancer drugs. This technology has the potentials of treating other local diseases and is expected to be used in clinical study in combination with some optoelectronic devices such as optical fibres.
About the research team
This study was led by Dr Wang Weiping, Assistant Professor of Dr Li Dak-Sum Research Centre and Department of Pharmacology and Pharmacy, HKUMed, and Principal Investigator of the State Key Laboratory of Pharmaceutical Biotechnology, HKU. Mr Long Kaiqi, PhD candidate of Department of Pharmacology and Pharmacy, HKUMed, and Mr Wang Yifan, MMedSc graduate of Department of Pharmacology and Pharmacy, HKUMed, are the co-first authors. Other researchers include Dr Lv Wen, Post-doctoral fellow of Dr Li Dak-Sum Research Centre, HKU; Mr Yang Yang, PhD candidate of School of Basic Medical Sciences, Fudan University; Ms Xu Shuting, PhD candidate of Department of Pharmacology and Pharmacy; and Professor Zhan Changyou of School of Basic Medical Sciences, Fudan University.
This work was supported by Hong Kong Research Grants Council - Early Career Scheme (No. 27115220), and Ming Wai Lau Centre for Reparative Medicine Associate Member Program.
Please contact LKS Faculty of Medicine of The University of Hong Kong by email (email@example.com).